CryoPort (NASDAQ: CYRX) announced disappointing quarterly results on March 12, 2024, with losses per share of $(1.31), far below analyst expectations. The company’s sales of $57.260 million also fell short of projections, marking a 5.13% decrease from the previous year.
Despite these challenges, CryoPort is optimistic about its prospects for the rest of 2024, forecasting revenue between $242 and $252 million. The company’s financial report for the fourth quarter and full fiscal year of 2023 showed a slight decrease in total revenue to $233.3 million, with the services business accounting for 62% of total revenue.
CryoPort’s focus on BioStorage/BioServices and commercial Cell & Gene therapies support has led to significant growth in these areas. The company is making strategic investments and forming partnerships to capitalize on the expanding Cell & Gene therapy industry, aiming to position itself for future success.
Cryoport Inc. (CYRX) Stock Price Declines After Hours: What Investors Need to Know
On March 12, 2024, Cryoport Inc. (CYRX) experienced a slight decrease in its stock price. The stock closed at $16.30, which was $0.08 lower than the previous market close, representing a 0.49% drop. Despite this decrease, CYRX is still trading in the middle of its 52-week range and above its 200-day simple moving average, indicating some stability in its performance.
However, after the market closed, CYRX saw a further decline in its stock price during after-hours trading. The stock dropped by $1.54, bringing its price down to $14.76. This significant drop after hours may indicate some volatility or negative sentiment surrounding the stock.
Investors and analysts will be closely monitoring CYRX’s performance in the coming days to see if this downward trend continues or if the stock is able to rebound. It will be important to assess any news or developments that may have influenced the stock’s price movement, as well as broader market conditions that could be impacting CYRX and its industry.
Cryoport Inc. (CYRX) Reports Positive Growth in Net Income and EPS on March 12, 2024
On March 12, 2024, Cryoport Inc. (CYRX) saw its stock performance reflect its recent financial results. The company reported a total revenue of $237.28 million for the past year, which was a 6.59% increase compared to the previous year. However, the total revenue remained flat at $56.16 million for the last quarter. Cryoport reported a net income of -$37.33 million for the past year and -$13.27 million for the last quarter. The net income actually increased by 86.45% since the previous year and by 27.71% since the last quarter. Cryoport’s earnings per share (EPS) also showed improvement, with an EPS of -$0.93 for the past year and -$0.31 for the last quarter, representing an 85.02% increase in EPS since the previous year and a 25.29% increase since the last quarter. Overall, Cryoport’s financial performance on March 12, 2024, demonstrated positive growth in terms of net income and earnings per share, despite the flat total revenue for the last quarter. Investors may view these results as a sign of potential long-term profitability and stability for the company. It is important for investors to conduct their own research and analysis before making any investment decisions.
